Home » Stocks » DVAX

Dynavax Technologies Corporation (DVAX)

Stock Price: $9.38 USD 0.13 (1.41%)
Updated Jun 24, 2021 3:25 PM EDT - Market open
Market Cap 1.05B
Revenue (ttm) 118.97M
Net Income (ttm) -61.75M
Shares Out 112.04M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE 34.25
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $9.38
Previous Close $9.25
Change ($) 0.13
Change (%) 1.41%
Day's Open 9.28
Day's Range 9.24 - 9.51
Day's Volume 1,283,709
52-Week Range 3.58 - 12.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Other stocks mentioned: NVAX, VXRT
1 week ago - The Motley Fool

EMERYVILLE, Calif., June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced th...

2 weeks ago - PRNewsWire

Saint- Herb lain (France ) , June 3 , 2021 –Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unm...

3 weeks ago - GlobeNewsWire

The company signed a key deal to market its hepatitis B vaccine in Germany.

4 weeks ago - The Motley Fool

Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, ...

Other stocks mentioned: BVNKF, BVNRY
4 weeks ago - Benzinga

EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it...

4 weeks ago - PRNewsWire

EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced th...

1 month ago - PRNewsWire

Saint- Herb lain (France) , May 19 , 2 021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant un...

1 month ago - GlobeNewsWire

The company announced the pricing of its senior convertible notes offering.

1 month ago - The Motley Fool

EMERYVILLE, Calif., May 11, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible...

1 month ago - PRNewsWire

The biotech announced a senior convertible notes offering.

1 month ago - The Motley Fool

EMERYVILLE, Calif., May 10, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $20...

1 month ago - PRNewsWire

The company's hepatitis B vaccine wasn't its key growth driver.

1 month ago - The Motley Fool

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

EMERYVILLE, Calif., May 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported fina...

1 month ago - PRNewsWire

EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares o...

1 month ago - PRNewsWire

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

EMERYVILLE, Calif., April 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced ...

1 month ago - PRNewsWire

EMERYVILLE, Calif., April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report firs...

2 months ago - PRNewsWire

EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announce...

2 months ago - PRNewsWire

Saint- Herb lain (France) , April 21 , 2 021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant ...

2 months ago - GlobeNewsWire

Saint- Herb lain (France) , April 20 , 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant u...

2 months ago - GlobeNewsWire

EMERYVILLE, Calif., April 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced ...

2 months ago - PRNewsWire

Investors cheered good news from the company's COVID-19 vaccine partner.

2 months ago - The Motley Fool

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

2 months ago - Zacks Investment Research

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.

2 months ago - Zacks Investment Research

Dynavax Technologies Corporation (NASDAQ: DVAX) has announced that Valneva SE reported initial results from Part A of the Phase 1/2 trial evaluating Valneva's COVID-19 vaccine candidate, VLA2001, using ...

2 months ago - Benzinga

EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced t...

2 months ago - PRNewsWire

EMERYVILLE, Calif., April 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 142,000 shares...

2 months ago - PRNewsWire

CHENGDU, China and EMERYVILLE, Calif., March 24, 2021 /PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing transformative biologics such as vaccin...

3 months ago - PRNewsWire

Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ: DVAX) have dosed the first participants in the SPECTRA trial of Clover's COVID-19 vaccine candidate adjuvanted with Dynavax's CpG ...

3 months ago - Benzinga

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, AYTU, CODX, CRTX, SRNE
3 months ago - Investors Business Daily

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ry...

3 months ago - PRNewsWire

EMERYVILLE, Calif., March 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the Company a...

3 months ago - PRNewsWire

The biotech's better-than-expected Q4 update pointed to even better days ahead.

3 months ago - The Motley Fool

The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.

3 months ago - The Motley Fool

EMERYVILLE, Calif., Feb. 25, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported fi...

3 months ago - PRNewsWire

Is (DVAX) Outperforming Other Medical Stocks This Year?

4 months ago - Zacks Investment Research

The company's hepatitis B virus vaccine won European Union approval.

4 months ago - The Motley Fool

EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced t...

4 months ago - PRNewsWire

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.

4 months ago - Zacks Investment Research

EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ry...

4 months ago - PRNewsWire

Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

4 months ago - Zacks Investment Research

EMERYVILLE, Calif., Feb. 8, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Don...

4 months ago - PRNewsWire

EMERYVILLE, Calif., Feb. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 7,500 shares of...

4 months ago - PRNewsWire

Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) b...

4 months ago - Benzinga

The biotech had lots of good news.

4 months ago - The Motley Fool

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. What Happened: China-base...

4 months ago - Benzinga

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.... [Read more...]

Industry
Biotechnology
IPO Date
Feb 19, 2004
CEO
Ryan Spencer
Employees
245
Stock Exchange
NASDAQ
Ticker Symbol
DVAX
Full Company Profile

Financial Performance

In 2020, DVAX's revenue was $46.55 million, an increase of 32.18% compared to the previous year's $35.22 million. Losses were -$75.24 million, -50.69% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is 18.67, which is an increase of 99.04% from the latest price.

Price Target
$18.67
(99.04% upside)
Analyst Consensus: Strong Buy